miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform is powered by the miR Sentinel® Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes.
Sam is co-founder of miR Scientific and is the company’s Chairman and Chief Executive Officer. A physics scholar who has dedicated his professional career to develop and manage complex systems innovations, Sam has established himself to be a true visionary driven to affect global impact. He is an accomplished world class leader who understands science and its business applications for resolving key challenges facing humanity on a global scale. A champion of public/private partnerships, he is a member of the Board of Trustees and Board of Selectors of the Jefferson Awards for Public Service. Sam attended the American University of Paris in France and Macalester College in St. Paul, MN.
Dr. Martin Tenniswood co-founded miR Scientific in 2013. As Chief Scientific Officer, Martin is responsible for the company’s overall scientific vision and research strategy. Martin also plays a key role in the translational research and commercialization processes and has been involved in many other areas of the organization in his role as a co-founder.
Martin previously spent 10 years as an Empire Innovations Professor in the Department of Biomedical Sciences at the University at Albany. Concurrently, Martin served as the Director of the Cancer Research Center at the University at Albany from 2009-2018. Previous to his tenure at the University at Albany, Martin was the Coleman Chair of Life Sciences at the University of Notre Dame from 1998-2007. Martin earned his Ph.D in Biochemistry from Queen’s University (Kingston, ON, Canada) in 1979, and his B.Sc (Hons) from Trent University (Peterborough, ON, Canada) specializing in organic chemistry in 1973.
He has authored and published more than 135 peer-reviewed papers and chapters and has edited two books. Since starting his independent career as a Canadian Medical Research Council Scholar at the University of Ottawa in 1983 Dr. Tenniswood’s research has focused on the study of hormone dependent cancers, including prostate, breast and endometrial cancer. His basic research focused on understanding the hormonal control of cell death in these cancers and in in developing new therapies for hard-to-treat hormone dependent cancers, particularly castration-resistant prostate cancer (CRPC) and inflammatory breast cancer. His lab has used a variety of high throughput, high content methodologies, including mRNA- and miRNA-based transcriptomics to understand the biology that leads to tumor progression and drug resistance.
In the course of his academic career he has mentored 31 graduate students, 19 residents and postdoctoral fellows, 47 of whom are still active in research.
Dr. Tenniswood has consulted for numerous commercial entities including Eli Lilly, Millennium Pharmaceuticals Cytochroma and Serono Pharmaceuticals and he has served as scientific reviewer for Medical Research Council of Canada, the National Cancer Institute of Canada, and the National Institute of Health (including the Pathology B study section and the NCI SPORE Review Panels).
Martin has served on the national Susan G. Komen for the Cure Review Panels and volunteered extensively with the local affiliates in Indiana and Northeastern New York region. In recognition of his contributions to the local affiliates he was awarded the status of Pink Tie Guy.
Erik Johnson, Chief Operating Officer, joined miR Scientific in 2021. A seasoned leader in pharma and oncology, Erik spent two decades at Bristol Myers Squibb, where he was instrumental in leading the global commercial scale-up of two groundbreaking immuno-oncology programs. Erik works closely with Co-Founder, Chairman & CEO Sam Salman to lead the Company's global operations, logistics, and enterprise resources for the planned high-volume production necessary for miR Scientific to deliver on its mission to transform cancer management worldwide.
Erik held several key leadership positions during his tenure at Bristol Myers Squibb, which included senior roles in strategy, planning, operations and commercial. As Head of Worldwide Commercial, Immuno-Oncology Melanoma & Genitourinary (GU), he was the worldwide lead for Opdivo® and Yervoy® in those tumors, totaling over $5B in annual revenue. He also worked closely with R&D to advance pipeline assets for Melanoma and GU. Throughout his career with BMS, Erik launched products for nine new indications, each of which exceeded company expectations. As the brand lead for SPRYCEL®, he drove and executed a strategy that delivered double-digit year-over-year growth, leading the brand to all-time highs in sales and market share.
Erik earned an MBA from the Merage School of Business at University of California, Irvine and received a Bachelor of Science degree from Colorado State University.
He is active in the Pennington, NJ community, where he served as an officer for the Hopewell Valley Education Foundation, actively supports underprivileged kids programs and participates in multiple running and cycling races each year, primarily benefitting cancer research.
Dr. Klotz is the past Chief of Urology at Sunnybrook Health Sciences Centre and Professor of Surgery at the University of Toronto. He holds the Sunnybrook Chair of Prostate Cancer Research, is the Chairman of the World Uro-Oncology Federation, and past president of the Urological Research Society and the Canadian Urological Association. He was the founder and is chairman of the Canadian Urology Research Consortium (CURC). Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. He was a fellow at Memorial Sloan Kettering Cancer Centre in New York in uro-oncology. Dr. Klotz is a widely published uro-oncologist with over 350 publications and 6 books. His main research interest has been prostate cancer. He is the Associate Editor of the Journal of Urology responsible for Prostate Cancer. He serves on the boards of many medical/scientific organizations and journals, including the SUO, Prostate Cancer Canada, the journals Prostate Cancer and Prostatic Diseases, Brazilian Journal of Urology, Italian Journal of Urology, and World Journal of Urology. Dr. Klotz was awarded the Queen’s Jubilee Medal for meritorious public service in 2012, and the University of Toronto Department of Surgery Lister Prize and the Society of Urologic Oncology Medal in 2013. He received the Harold Warwick Award from the Canadian Cancer Society for "outstanding contributions to cancer control" in 2014. He received the Order of Canada in 2015 and the Richard Williams Award from the AUA in 2016. He received the Dean’s Lifetime Achievement Award from the University of Toronto in 2017.
Tal is a seasoned impact investment professional with broad transaction experience that spans industries, sectors and geographies. His roots in the sustainability and healthcare sectors run deep, with corporate leadership roles and prominent presence as investor, advisor and board member in companies and investment funds. As Chief Strategy Officer of miR Scientific, Tal draws on his extensive experience in structuring transactions to craft, articulate and execute strategic dialogues and commercialization initiatives for miR. Tal received his M.B.A. with distinction from New York University’s Stern School of Business and his B.A. degree magna cum laude in Economics from Queens College.
Deborah Fine is Chief Corporate Affairs Officer, joining miR Scientific in 2018. Fine is also President, Global Impact for Impact NRS, the parent company of miR Scientific. Deborah interprets how stakeholders view and understand the Company and its products, defining and protecting the corporate brand and its reputation. She develops strategy and forges relationships to best connect miR Scientific’s actions with a diverse and ever-expanding set of external constituents. Aligned with her parent company role, Deborah has a particular focus on global impact and innovation, measuring Environmental, Social and Governance (ESG) metrics and mapping its contributions to the United Nations Sustainable Development Goals (SDGs).
Deborah is a dynamic executive and proven CEO, leading six diverse B2B and B2C businesses to record growth and profit in both public and private enterprises, ranging from start up to $1 billion in revenue, in companies including Avon, Condé Nast, and NBC Universal.
Fine has served on the Women’s Leadership Board of the Harvard Kennedy School’s Women and Public Policy Program since 2015 and was nominated to the Executive Committee of the Board in 2019. The Women’s Leadership Board is focused on closing gaps in economic opportunity, health and education worldwide.
Deborah has received numerous national leadership and commercialization awards from organizations including Advertising Age, American Legacy Foundation, Cosmetic Executive Women, Girl Scouts, United Cerebral Palsy Foundation and Women’s Wear Daily. She is a member of the prestigious International Women’s Forum and has been selected for the Distinguished Speaker Series at Harvard, Yale, Wharton, and Columbia. Her work has been featured in many national outlets including The New York Times and The Wall Street Journal.
She has served on the boards of eight businesses and organizations in the medical research, consumer products, marketing, media, and financial services sectors. Deborah is committed to improving treatment and finding a cure for diabetes, serving on the board of the Juvenile Diabetes Research Foundation, the University of Pennsylvania Institute for Diabetes Leadership Council, and raising over $2 million via grassroots leadership.
She is a cum laude graduate of the University of Massachusetts at Amherst.
Jill Anderson is Chief Legal Officer, joining miR Scientific in 2020. Jill oversees the company’s global legal operations and advises the company’s leadership on a wide range of strategic legal, regulatory and business issues.
Jill has nearly twenty years of legal experience in healthcare technology and biotechnology, with specific expertise advising cutting-edge, high-profile bioscience companies and diagnostic laboratories. She most recently served as a partner in the Healthcare and Privacy & Cybersecurity departments at law firm Moses & Singer LLP in New York City. While at Moses & Singer, she acted as outside general counsel to several life sciences companies, including nonprofit research foundations.
Prior to joining Moses Singer, Jill held roles at Partners Healthcare System and Dana-Farber Cancer Institute in Boston, where she handled legal issues related to clinical and translational research. She began her career as a securities lawyer at Hale and Dorr LLP (now WilmerHale).
Jill earned her J.D. at Widener University School of Law and holds a Bachelor of Science degree in Pre-Medicine from Rutgers University. Jill is very active in the life sciences startup community, frequently volunteering to advise and mentor emerging companies on regulatory and legal issues related to product development.
Bob Flippin formally joined miR Scientific in 2020, after serving as a Senior Advisor to the company for several years. Bob supports oversight of miR Scientific’s strategic direction and growth, implementing company strategy across financial, legal, facilities and general personnel domains.
Bob came to miR Scientific after a long career in commercial real estate, most recently as Executive Vice President of CBRE Group, Inc., the largest commercial real estate services and investment firm in the world. Based in New York City, Bob has represented large international corporations on a local, national and global basis.
He has worked on significant complex transactions involving leases, portfolio analyses, property valuations and acquisitions, and corporate impact studies across real estate asset classes around the world. His vast global business network has also led to the development and expansion of numerous businesses, in addition to his real estate dealings.
Bob earned his Bachelor’s degree in History and Economics from Princeton University, where he captained the lacrosse team and earned All-American and All-Ivy honors.
Outside the workplace, Bob supports youth sports activities, including coaching on multiple levels, and sponsoring inner-city youth groups that combine education with sports to expand opportunities for underprivileged children to pursue secondary and college education.
Eli Mor, General Manager, miR Scientific Israel, joined the company in 2019. Eli is responsible for all of miR Scientific’s activities in Israel, supervising business development, marketing and operations.
As an executive, Eli has raised capital, executed and integrated acquisitions, established corporations in new arenas and grown revenue. He has developed and launched new product lines, gained immediate market traction, executed turnaround strategies and changed management practices to drive sales.
Eli joined Impact NRS Group as President and Head of International Operations 5 years ago, and serves its subsidiaries as Co-Founder and President of NRS Agro-Innovation and CEO of NRS Poultry Sustainability & Transformation. In these capacities, Eli brings powerful data science, informatics and agriculture together to provide solutions for the world’s most pressing problems.
Previously, Eli spent 7 years at BioHarvest as CFO and prior as Senior Vice President of Business Development, where he led significant fundraising and played an instrumental role in company strategy. Eli has also held senior executive roles at Explay and Terayon Communications Systems.
Eli is a board member and venture partner at EFA Technologies. He holds a Bachelor of Arts in Accounting and Business Administration from the College of Management Academic Studies and is also a Certified Public Accountant.
Dr. A. Gregory DiRienzo is a co-founder of miR Scientific and serves as the company’s Director of Biostatistics. Greg’s primary responsibilities concern the rigorous development of modern statistical methodology and the design of corresponding software implementations for targeted use in data applications such as high dimensional classification and prediction; longitudinal studies with missing data; and survival analysis. Greg establishes protocols for the design and analysis plans of miR’s clinical studies.
Greg spent 21 years in academia, most recently as a full-time faculty member in the Department of Epidemiology and Biostatistics, University at Albany - State University of New York, where he served as chairman from 2011-2017. He was previously a full-time faculty member in the Department of Biostatistics at Harvard University from 2001-2008.
Greg has published numerous peer-reviewed articles in leading biostatistics and medical journals and is co-author on several patents with miR Scientific. He completed his Ph.D. in both Mathematics & Statistics and Biometry & Statistics at the University at Albany - SUNY and his Postdoctoral Research Fellowship with the Department of Biostatistics at Harvard University.
Greg is active in his local community, where he volunteers as a tee-ball coach and ice-hockey instructor for young children, as well as actively participating in local food banks for those in need.
Dr. Nathalie Bloch is Head of Discovery Platform at miR Scientific and Chief Medical
Innovation Officer at parent company Impact NRS Group, joining the company in 2021.
Nathalie is an industry leader in the digital health and AI in healthcare ecosystems in Israel.
She spent the last 4 years as Founder and Director of the Innovation Center for Digital Health
ARC at Sheba Medical Center and was responsible for building the hospital’s big data and AI
infrastructure, collaborating with dozens of startups, academic institutions and international
companies. Nathalie also served as the Director of the Patents Committee at Sheba Medical
Nathalie spent 14 years as a physician at Harvard Medical School, with 4 years as an Associate
Medical Director at MACIPA in Cambridge, MA, where she led strategic projects to implement
new technologies within the organization, reducing readmissions and moving care into the
Nathalie is part of a national committee advising the Israeli government on establishing its
strategy for the next decade on Bioconvergence in Healthcare. She leads an educational
practicum-based innovation and entrepreneurship program for medical residents at the
Israeli Medical Association, where she integrates 20 residents into 20 startups each year.
Nathalie is additionally a senior advisor to the Israeli Ministry of Health for R&D projects in
Innovation, Data and AI.
In 2018, Nathalie ranked among Haaretz’s 20 most influential women in healthcare in Israel.
She serves on the boards of leading Israeli startups in AI in healthcare.
Nathalie earned her Doctor of Medicine from Tel Aviv University and a Master in Public
Administration from the Harvard Kennedy School of Government. She was also a Senior
Fellow for Innovation in Healthcare Delivery at Harvard Medical School.
Nathalie is active with Physicians for Human Rights-Israel and volunteers in the Occupied
Territories and the refugees’ clinic.
Rob Tenniswood is the Co-Founder of miR Scientific, and serves as President of the company’s Canadian subsidiary, miR Scientific Canada. In his current role, Rob is responsible for all Discovery operations, strategy and tactical execution, all efforts to introduce miR Scientific’s Sentinel platform in Canada (including government and stakeholder relations, regulatory submissions, clinical trial implementation, and all business operations). He previously spent 7 years as the company’s Chief Operating Officer, and was responsible for oversight of all of the company’s internal operations, including oversight of finance, human resources, vendor relations, project management and strategy.
Rob earned his MBA in 2009 from the University of Notre Dame (South Bend, IN), and his B.A. from Notre Dame in 2005. He is also a graduate of the Entrepreneurship post-graduate program at the University of Cambridge, having graduated in 2015.
Rob actively supports several non-profit organizations, including Hug-A-Bull Dog Rescue, Black Lives Matter, Covenant House, and Plan International.
Amnon is the Head of Global Clinical Affairs, joining miR Scientific in 2021. Amnon plays a key role in developing and leading the company’s clinical operations in compliance with global regulatory standards.
Amnon spent 12 years at companies in the pharmaceutical and biotech industry, most recently as Director of Clinical Operations at Eloxx Pharmaceuticals where he led clinical operation functions in North America, Europe, Australia, and Israel.
Amnon earned his PhD from the Hebrew University of Jerusalem and spent 3 years as a postdoctoral fellow at the University of California, Los Angeles (UCLA)
Winnie is Director of Research, joining miR Scientific as Employee #1 in 2017. She previously spent 3 years as the company’s Research Lead and was responsible for the miR Sentinel® Prostate Cancer Test design and process optimization for commercialization.
Winnie has published and authored 11 peer-reviewed articles.
She received her doctorate degree in Biomedical Sciences from the State University of New York at Albany, where she received both the distinguished doctoral dissertation award and academic excellence award for her thesis. Winnie earned her Bachelor of Science degree in Biochemistry from Queen's University in Canada.
Rob Francess, Global Controller, joined miR Scientific in 2018. A Certified Public Accountant, Rob brings over 25 years of experience building and leading all stages of finance, accounting, operations, and reporting for small to mid-sized organizations.
Rob spent 10 years as Chief Financial Officer for M.D. Sass Investors Services and GTI Group, LLC, two global private equity funds managing in excess of $9B. Serving on the funds’ Executive Committee, Rob played a key role developing the company’s finance, accounting, and reporting operations. He served on the board of several portfolio companies, where he also held the role of interim CFO.
Rob also has expertise in investor relations through his work on product promotion, capital raises and performance reporting, as well as handling investor tax reporting.
Rob obtained a Bachelor of Business Administration cum laude in Accounting from Iona College.
Rob is active in the South Shore of Long Island’s charitable community, volunteering and organizing with St John Nepomucene Church’s Parish Outreach Center.
John Dvor, Executive Vice President, Corporate Development, joined miR Scientific in 2020. John is responsible for miR’s international business development and strategic alliances with providers, payers, academic institutions, governments and corporations.
John brings over 20 years of experience as an entrepreneur, investor and advisor focused on the spaces of medical science and life-saving technology. Most recently, he co-founded Tufts Health Ventures, the investment arm of $4B health insurance company Tufts Health Plan. At Tufts Health Ventures, John was responsible for venture investments, strategic partnerships, including the creation of new payer/provider joint ventures nationwide, focused on value-based care. John served as Managing Director of Miraki Innovation, a med-tech venture capital fund which founded Auris Health, acquired by Johnson & Johnson for $5.75B. As an entrepreneur, John previously co-founded and was COO of ReMed Life Sciences, focused on auto-immune therapeutics for vitiligo patients.
John has held multiple roles in corporate leadership, from Head of Corporate Development for 3BL Media, a leading ESG/CSR digital media platform serving 60% of the Fortune 500, to corporate development roles at iRobot Corporation and the Aga Khan Development Fund.
John earned a Bachelor’s degree from Harvard University, beginning his early career as a United States Secret Service Attaché with the Marine Corps in the White House. Serving during the Clinton and Bush administrations, John was awarded Presidential Service Badge #17996.
John serves on the boards of the Association for Corporate Growth, the New England Israeli Business Council, Agon Holdings and Helge Capital. His work has been featured in the Financial Times, Boston Globe and the Wall Street Journal.
John is a board member for two national workforce development nonprofits, the Warrior Scholar Project and Defy Ventures.
Austin Srejma, Vice President Commercial, joined miR Scientific in 2020. Austin leads the development and implementation of the go-to-market plan and commercial strategy for miR’s Sentinel family of tests, focused on the US launch market as well as worldwide readiness. In addition, she leads the company’s program management office to plan and execute special projects.
Prior to joining miR, Austin spent over a decade at Enterey Life Sciences Consulting, most recently as Senior Director of Operations where she led the consulting organization to develop methodology and deliver strategic business transformations for top-tier established and emerging life sciences companies with domestic and global impact. She played a central role in consulting project scoping and delivery, internal recruiting, training, business development, marketing, and organizational development efforts.
Austin earned a Master of Business Administration from the University of Notre Dame, where she was a member of Beta Gamma Sigma academic honor society, and received a Bachelor of Arts in Biology from Gustavus Adolphus College.
In 2020, Austin joined the inaugural group of Mendoza Graduate Alumni Leadership Fellows, coaching MBA students in leadership development. She is a member of the Chicago chapter of Women in Bio and the Executive Women in Bio sub-group.
Austin is active in the Chicago philanthropic community, supporting food-security and poverty-alleviation charities including Inspiration Corporation, the Greater Chicago Food Depository, and CARA. Additionally, she is a member of the Alzheimer’s Association Alois Society.
Scot Nelson is Vice President of Global Market Access and US Commercial Launch Lead. Scot joined miR Scientific in mid-2021 brings more than 20 years of industry experience in the commercialization of pharmaceuticals and diagnostics across a variety of specialties including Oncology, Urology, Gastroenterology, Dermatology and Primary Care to the miR Team.
He most recently served as Senior Director of Managed Care at Decipher Biosciences, Inc. where he was responsible for the development and execution of Decipher’s Managed Care Strategy to increase public and private payer adoption of Decipher’s genomic assays for urological cancers. In addition to his core responsibilities, Scot served as a strategic advisor to the Executive Team in the areas of Commercial Operations, Sales, Marketing and Revenue Cycle Management and served on numerous cross-functional teams in support of Decipher’s overall corporate strategy. As a result of his efforts, Decipher experienced significant gains Medicare and Commercial Coverage and Commercially Contracted Lives, as well as a 5-year contract awarded by the U.S. General Services Administration and Federal Supply Schedule to serve the Veterans Administration as well as other Federally Affiliated Health Systems. His contributions significantly increased per-test and overall reimbursement for Decipher’s genomic assays, contributed significantly to the company becoming profitable in mid-2020. and delivered a significant return to investors through a successful acquisition of Decipher by Veracyte, Inc. in early 2021.
Scot spent 13 years at Prometheus Laboratories where he successfully launched multiple CLIA Diagnostic and 3 Specialty Pharmaceutical Offerings in the areas of Gastroenterology, Urology and Oncology, achieving peak revenue of $500 million dollars, while serving in roles of increasing responsibility in Sales, Managed Care, Corporate Accounts and Business Development. He also served as a member of Nestle Health Sciences Global Market Access and Strategy Committee representing Prometheus RxDx as part of the Global Market Access Team. Prior to Prometheus, Scot held Field Sales and Sales Training roles for Connetics Corp. and Healthpoint, Ltd and served honorably in the United States Navy.
Scot has been active in the Mobile, AL community since 2006 having served on multiple boards including the Mobile Chapter of the Coastal Conservation Association and The Port City Pacers. He has also served as a volunteer consultant to medical practices as well as multiple early-stage diagnostic and health technology startups in the areas of Market Access and Business Development.
Scot graduated cum laude with a Bachelor of Science in Management of Technical Operations from Embry Riddle Aeronautical University.
Avital Barlev, Vice President of Quality Assurance, joined miR Scientific in 2020. Avital previously spent 11 years at Alpha Bio Tec Ltd., most recently as Vice President leading the company’s Quality Assurance department according to the United States Food and Drug Administration (FDA), the European Union, the ISO and other medical device regulatory authorities.
As a quality assurance leader, Avital has a demonstrated history of establishing and maintaining efficient quality systems in highly regulated markets and a track record of building teams under fast-growing business operations. At Alpha Bio Tec, he built the quality assurance function from the ground up, setting up three teams under a lean management system and priming the company for new medical device regulations in its primary market, the European Union. During his tenure, Alpha Bio Tec tripled its sales and production capacity while keeping high standards of quality and compliance.
Avital earned a Bachelor degree in Biotechnology from Tel-Hai College.
Outside of work, Avital enjoys playing soccer and running mountain trails with his dog.
Eytan Meisels is Vice President of Regulatory Affairs, joining miR Scientific in 2020. He previously spent over 20 years at Inverness Medical Innovations, Alere and Abbott as VP of Regulatory Affairs and Quality Assurance where he led regional teams and was responsible for quality and regulatory strategies in various global regions, including achieving regulatory approvals for high risk In Vitro Diagnostic Medical Devices in the USA, EU, Latin America, Africa and Eastern Europe.
He plays a key role in defining integrated global regulatory strategies for company products and the continued development of regulatory strategy and relationships with regulatory authorities, ensuring flexibility in response to an increasingly demanding regulatory environment.
Eytan has been in the medical device industry for 25 years, most recently as VP of Regulatory Affairs and Quality Assurance at VisionCare (now SamaraVision) where he led the company program of getting CE Mark for a novel intraocular implantable miniature telescope.
He has co-authored peer-reviewed articles in the fields of chemical spatial structures and gene regulation.
Eytan earned his Ph.D. from the Weizmann Institute and was a Howard Hughes Postdoctoral fellow at the Johns Hopkins University School of Medicine. He received a Master of Science degree from the Hebrew University in Jerusalem’s Hadassah Medical School and a Bachelor of Science degree in Chemistry and Biochemistry from the Hebrew University in Jerusalem.
Eytan is active in the Rehovot Berman community, where he served on the board and as president of the board. He continues to volunteer and lead various community activities.
Dr. Northrop is VP of Operations, joining miR Scientific in 2022
At mir Scientific, Dr. Northrop plays a key role in ensuring all operations of mir Scientific meets the scientific integrity, regulatory quality and state-of-the-art technology of the miR SentinelTM Prostate Cancer Test into transforming oncology testing access worldwide.
Prior to joining miR, Dr. Northrop spent the past three years as Chief Scientific Officer at Aspira Women’s Health and was responsible for all of the company’s innovation pipeline from ideation in R&D to clinical diagnostic validation and product launch.
Dr. Northrop has spent over 20 years in the clinical diagnostic industry specific to women’s health, including her ABMGG training at Columbia University Medical Center, and building six brand-new CLIA/CAP/NYS molecular laboratories for several start-up biotechnology companies revolutionizing cutting-edge new technology. As an Innovator Dr. Northrop was a lead scientist on developing the first comprehensive PGD technology as a more diagnostic representation of an embryo’s ploidy status and single-gene variant detection while a post-doctoral fellow at RMA-NJ Fertility Center. Dr. Northrop as a young scientist served as the lead field biologist in helping the first Giant Panda baby born in captivity at the San Diego Zoo and first eleven panda cubs born at the Woolong Nature Reserve in China. She has published several peer-reviewed articles, book chapters and presented at several prestigious scientific meetings.
Dr. Northrop serves as an advisor to several biotechnology and financial investment firms on her expertise in the clinical diagnostic genomics space.
Dr. Northrop mentors young minds in science and leads her teams to insight with empathy.
Arminda Figueroa is Chief of Staff and Country Manager, joining miR Scientific in 2019. Mindy was essential in launching miR Scientific’s inaugural clinical trial program in Puerto Rico and plays a key role in the company’s path to commercialization.
Mindy brings over 20 years of experience in marketing and communications, with an emphasis on diversity, equity and inclusion, healthcare, and Hispanic and multicultural marketing. Mindy founded award-winning consulting firm Latin2Latin Marketing (L2L) 14 years ago as a market-growth accelerator, successfully developing and executing hundreds of complex strategic plans for a client base ranging from startups to corporations.
Her work on healthcare and patient education has appeared in publications such as Bloomberg, the Miami Herald, the Huffington Post and networks including Telemundo and Univision. In 2020, Mindy co-authored a study by the Network for Executive Women on the experiences of Latina women in corporate America. Mindy also frequently lends her expertise on podcasts and local South Florida radio.
Mindy serves on the boards of the Center for Hispanic Marketing Communication at Florida State University, the Hispanic Entrepreneur Initiative, and is Vice Chair of the Board of Governors of Tower Club. She is a member of Invest4PR and the Partnership for Modern Puerto Rico. She was recently honored by South Florida Business and Wealth Magazine as a recipient of their 2021 Prestigious Women Award.
Mindy holds a Master of Business Administration from Dowling College in New York and a Bachelor’s degree from the University of Puerto Rico.
Mindy is active in both the Florida and Puerto Rico communities, and served as an advisor to Gov. Rick Scott on the South Florida relief efforts for Puerto Rico after the devastation of Hurricane Maria. She is the proud founder of the grassroots philanthropic organization, Adopt a Puerto Rican Family.
Stuart Kozlick, Senior Vice President, Canada, joined miR Scientific in 2020. Stuart supports miR’s commercialization efforts in Canada.
Stuart brings over 20 years of experience in medical device development, innovation, research and commercialization. Stuart’s subject matter expertise spans several medical specialties including electrophysiology, structural heart, cardiovascular, endovascular, pulmonary, gastrointestinal, orthopedics and minimally invasive therapeutics. Over the course of his career, Stuart has launched several research, product development and clinical engineering programs and products globally.
In 2019, Stuart became the CEO of Puzzle Medical Devices Inc., a Montreal-based startup specializing in the development of cardiovascular medical devices to treat advanced heart-failure patients. Previously, Stuart was Vice President of Medical Robotics at Kinova Robotics Inc. in Montreal. Stuart has also served in several leadership and engineering roles at CAE Healthcare, Medtronic Inc., and the former CryoCath Technologies Inc.
Stuart serves as Professor of Practice in McGill University’s Faculty of Medicine & Health Sciences, Department of Surgery, Faculty Lecturer in the University’s Faculty of Engineering, Departments of Bioengineering and Mechanical Engineering and the Faculty of Management, Dobson Centre for Entrepreneurship.
Stuart continues to support the growing medtech ecosystem within Quebec and more broadly in Canada, holding various board positions, advising and mentoring L’institut TransMedTech, CTS Santé, RTI Inc., and TechStars Montreal AI, among others. Stuart also serves as Strategic Advisor, Executive-In-Residence within the Emerging Technology & Startup practice at Fasken Martineau DuMoulin LLP.
Stuart holds a Master of Applied Science in Mechanical Engineering and a Bachelor of Engineering from Concordia University.
Stuart dedicates his time in the fields of cardiology and interventional cardiology with specialists, volunteering his presence in operating rooms during procedures, contributing to new interventional workflow creation and innovative future cardiac technology.
Recently, Stuart was honored to co-lead the McGill University COVID-19 Code Life Ventilator Challenge in 2020 and 2021, a voluntary global response initiative with over 1,200 submissions, resulting in next-generation low-cost ventilator design for patients in need.
Avivit Raz joined miR Scientific in 2021 as Executive Vice President of Business Development in Israel. Avivit plays a key role in the company’s business strategy and operations in Israel, supporting commercialization efforts in the country.
Avivit’s experience in the pharmaceutical and molecular diagnostics industries covers marketing, sales, and business development functions in local as well as international corporate settings such as Merck and Janssen (J&J). With over a decade spent in the healthcare industry, Avivit has developed and implemented strategy, led reimbursement processes, and launched significant oncology products.
Avivit received her MBA from Ben-Gurion University, her MSc in Biology with distinction with a concentration in Genomics from Bar-Ilan University, and a bachelor’s degree in Biology with distinction from Ben-Gurion University.
In her capacity as a board member in the space of personalized medicine, Avivit worked to promote testing and expand its accessibility, recognizing that personalized medicine is the optimal path for diagnosing and treating various medical conditions.
Akira Tsukagawa is Head of miR Scientific Japan, joining miR Scientific in 2021. He is responsible for all of miR Scientific’s activities in Japan.
Across a career spanning three decades, Akira has focused on building open innovation and connecting Boston, Silicon Valley and Europe with Japan and the Asia-Pacific region. He founded Open Innovation Partners and co-founded Seize Capital in 2015. Akira has also served as venture firm Miraki Innovation’s Director for Japan for the last two years.
Since 2014, Akira has specialized in healthcare, InsurTech and AI, promoting open innovation at OMRON and Sompo Holdings, mainly overseas. As Founder at Open Innovation Partners, he led Sompo’s investment in Health2Sync, which is now partnered with Sanofi, Novo Nordisk and Abbott and has become the number 1 diabetes solution in Asia. He also led Sompo’s investment in Neurotrack Technologies, a mild cognitive impairment (MCI) and dementia solution, ultimately launching Neurotrack as an MCI insurance product in Japan. In addition, Akira facilitated the adoption of medical and healthcare AI platform, Hathor, for the development of a Japan Medical Association AI platform by the government of Yamanashi prefecture.
He previously served as Director of SBI Holdings for India and in the principal investment at Deutsche Bank and Lehman Brothers. While at Deutsche Bank, Akira managed Softbank CEO Masayoshi Son’s Vodafone M&A. Prior to these roles, he was Vice President at Nomura/JAFCO Investment (Asia) Ltd.
Akira earned his MBA from Columbia University and is a U.S. Chartered Financial Analyst. He also holds an Executive MBA from UC Berkeley’s Haas School of Business in Data Science & Analytics and Innovation.
Keren Nir works as Vice President, Operations for miR Scientific Israel. Keren holds a Master’s degree in Business Administration (MBA) from Heriot-Watt University, and is an expert in business mediation, strategy and business analysis. Keren also holds a Master's of Law from Bar-Ilan University.
Sebastiano is an entrepreneur, investor, activist, and advisor to businesses, governments, and nonprofits around the world. He is the chairman and CEO of NKGB, a strategic advisory firm specializing in Asian and European ventures as well as global M&A.
Directly or through his partnerships, Sebastiano is an investor in over 60 companies in the plant-based and cruelty-free space alone, and was an early investor in Beyond Meat (2012).
He is the owner and honorary chairman of Querciabella, a Tuscan organic, biodynamic, and vegan winery that has garnered international acclaim and won numerous awards, including “Best Wine of Italy,” and recently launched the gluten-free pasta brand Bontasana alongside a revolutionary baby food company, with the aim to disrupt the existing landscape.
A longtime animal rights activist, Sebastiano supports and sits on the board of several global nonprofits working to end the exploitation and suffering of animals. He is also the founder of the Plant-Based Empowerment Foundation (PBEF), a nonprofit operating in rural Senegal that is dedicated to providing children and women access to education, healthcare, and nourishing plant-based food.
Sebastiano served as advisor to Italian Prime Minister Matteo Renzi from 2014 to 2016. Originally from Milano, he divides his time among Europe, Asia, and the United States.
Arun is an entrepreneur, investor and technologist focused on Blockchain, Artificial Intelligence, AR/VR , IT software and infrastructure for enterprise, data analytics, cloud platform, open source technologies, healthcare and sustainable energy, and is the Chief Executive Officer / Chief Risk & Compliance Officer of Leonie Hill Capital.
He has over 26 years of experience as a product centric founder, General Manager and CEO at startups and Fortune 500 companies in the US, Europe and Asia.
Arun has a diverse background in building enterprise focused startups, and has extensive operational experience in expanding companies in Asia and the emerging markets with a strong understanding of local laws, cultural and market demands, His experience in investing in disruptive startups, coupled with strong financial industry experience from trading to debt financing and equity research has also made him a well recognized and respected quant.
Being a mentor to entrepreneurs building technology-based businesses is Arun’s greatest passion. He is driven by the desire to make a positive impact through helping the entrepreneurs building and scaling businesses focused on new energy sources, achieving petroleum independence, building sustainable medical ecosystems, and promoting pragmatic approaches to environmentalism.
Additionally, he has taken a special interest in micro-finance as a poverty alleviation tool, because of his fervent dedication to social entrepreneurship. He is a supporter of many micro-finance organizations in India, Africa and the Middle East, and is actively building software companies to help them manage and grow in these regions.
He also acts as a liaison officer between the firm and various regulators on matters relating to Anti-Money Laundering/Countering Financing Terrorism etc., advising on implementation of best practices particularly with regards to AML/CFT regulations, and ensuring compliance with laws & ordinances.
At Leonie Hill Capital he developed robust investment decision making processes, on-going portfolio monitoring, evaluation and back office infrastructure to manage large in house portfolios.
Arun has an MBA from Stanford University and a B.Tech. in Electrical Engineering from IIT, Madras.
Dr. Deepak A. Kapoor, Chairman and Chief Ecosystem Officer of Solaris Health Holdings, LLC, is one of the youngest physicians to have been certified by the American Board of Urology. In addition to his role at Solaris Health, Dr. Kapoor serves as Market President for Integrated Medical Professionals, PLLC (IMP) and is President of Advanced Urology Centers of New York.
Dr. Kapoor received his baccalaureate and medical education with honors in the Pennsylvania State University/Jefferson Medical College accelerated honors program in medicine and completed his urologic residency at The Geisinger Medical Center in Danville, PA. His expertise includes basic science research in molecular biology, as well as extensive experience in oncologic and reconstructive surgery
Dr. Kapoor is Clinical Professor of Urology at the Icahn School of Medicine at Mount Sinai, Chair of Health Policy and Past President of LUGPA, Chairman of SCRUBS RRG and Senior Strategic Advisor for miR Scientific. He has also served as a Director of UroPAC and Chairman of Access to Integrated Cancer Care. Dr. Kapoor was founder of the New York Urology Trade Association and Integrated Medical Foundation. He is a Fellow of the American College of Physician Executives.
Dr. Kapoor has published and lectured extensively on clinical, business and health policy issues and is Associate Editor of the journal Urology Practice. He serves on a number of medical advisory boards, including the New York State Governor´s Prostate Cancer Advisory Panel. Dr. Kapoor has been continuously listed in the Castle Connolly Best Doctors Guide for his clinical excellence and has received numerous accolades, inlcuding the 2011 AUA Ambrose-Reed socioeconomic essay award, and the 2014 New York Section AUA Russell W. Lavengood distinguished service award. Dr. Kapoor was recognized in 2018 by LUGPA for his outstanding contributions to health policy and his work towards the preservation of independent medicine.
Jim Roosevelt joins miR Scientific with extensive executive and advisory experience in health care, life sciences, corporate governance, legislative and regulatory matters, and politics. Jim served as CEO of Tufts Health Plan for more than 10 years, where he led a corporate turnaround that achieved significant growth and consistent profitability for the company. Before joining Tufts Health Plan, Jim served as Associate Commissioner of the U.S. Social Security Administration, and he was in-house General Counsel and former partner in Choate Hall & Stewart, a leading national law firm based in Boston.
Jim is passionate about politics and public policy. He is a clinical instructor in the Public Health and Community Medicine Department of Tufts University School of Medicine. He co-chairs the Rules and Bylaws Committee of the Democratic National Committee, is volunteer legal counsel for the Massachusetts Democratic Party, and is a trustee of the Cambridge Public Library and the Cambridge Community Foundation. Additionally, Jim is a member of the FAIR Health, Inc. Board of Directors, and he serves as Chair of the Massachusetts Health Quality Partners Board of Directors.
Jim is a member of the American Health Lawyers Association, the Boston Bar Association’s Health Law Committee, and the American Bar Association’s Health Law Section.
Previously, Jim has been a visiting fellow at the Institute of Politics of the Harvard Kennedy School of Government, co-chaired Rhode Island Governor Gina Raimondo's Healthcare Leaders Task Force on Health Care Cost Growth and co-chaired the Massachusetts Hospital Association's work group on access to behavioral health care.
Jim earned a J.D. from Harvard Law School, and he earned his B.A. from Harvard College. He also graduated from Harvard Business School’s Advanced Management Program.
Mr. Weinstein is focused primarily on international business development for Vanterra Accelerator portfolio companies. Mr. Weinstein has more than 30 years of experience in the healthcare and wellness industries, both operational and investing. Mr. Weinstein co-founded WM Partners in 2015, a leading health and wellness focused private equity fund. Previously, Mr. Weinstein was the CEO of CFR Pharmaceuticals S.A. (“CFR”) for ten years, where he was responsible for transforming that company from a local Chilean pharmaceutical company into a major global pharmaceutical company with a presence in 26 countries and three continents, via 15 acquisition transactions. Under Mr. Weinstein’s leadership, in May 2011 CFR completed an initial public offering, one of the largest IPOs in Chile. In September 2014, Mr. Weinstein led the sale of CFR to Abbott Laboratories for approximately $2.9 billion.
Mr. Weinstein has been active in developing and managing several businesses and start-up companies via joint ventures with local and foreign R&D companies. Mr. Weinstein has served as a board member in several businesses within the pharmaceutical industry and other industries in three continents.
Mr. Weinstein received a Business and Administration degree from the Universidad Catolica de Chile, and is a certified public auditor and accountant. He participated in the Owner/President Management Program at Harvard Business School.
Mr. Weinstein has more than 10 years experience as executive and investor in the life sciences industry. He most recently served as Vice President of Innovation and Development at Abbott Laboratories. Prior to that he was Vice President of Strategy and Innovation at CFR Pharmaceuticals. He has a proven track record of launching over 300 products in the Pharmaceutical industry in Latin America and completing more than 20 licensing deals including Biotech products and Medical Devices.
He currently serves as a Board Member of Arterys, Convexity Scientific, Hygieacare and Medasense. He previously was a board member of BMRC, a biotech research consortium in Chile.
Dr. Andrew Armstrong is a tenured Professor of Medicine, Surgery, Pharmacology and Cancer Biology and Director of Research for the Duke Cancer Institute’s Center for Prostate and Urologic Cancer. He is a medical oncologist and internationally recognized expert in experimental therapeutics and biomarker development in genitourinary cancers, particularly in prostate cancer. He trained at Duke as a biomedical engineer, received his medical degree at the University of Virginia, medicine residency training at the University of Pennsylvania, fellowship and public health clinical investigation training at Johns Hopkins and the Bloomberg School of Public Health, and joined Duke’s faculty in 2006.
As a clinical and translational investigator, he is focused on experimental therapeutics for patients with advanced genitourinary malignancies, particularly with a focus on prostate and kidney cancer and the investigation of biomarkers of response and benefit both in the laboratory and in the clinic. He is funded by the US Department of Defense, PCF/Movember, the NIH, and the American Cancer Society for his work on circulating tumor cell biology and epithelial plasticity. He led the development of enzalutamide and FDA approval for men with metastatic prostate cancer and studies hormone resistance in the laboratory and ways to overcome this in the clinic. He was a Prostate Cancer Foundation, AACR, and ASCO Young Investigator Award recipient. He co-chaired Prostate Cancer Working Group 3 which established guidelines in 2016 for clinical research in advanced prostate cancer, and is a leading writing member of the NCCN Prostate Cancer panel since 2012 for national clinical guidelines on the treatment of men with prostate cancer.
Dr. Armstrong has developed a number of experimental agents in prostate and renal cell cancer, including completed or ongoing trials of AR inhibitors, immunotherapies, mTOR/PI3K inhibitors, and anti-angiogenic agents, and is heavily involved in the leadership of multiple ongoing phase 1-4 treatment and biomarker trials in men with advanced prostate cancer including serving as correlative science chair within the NCI ALLIANCE Cooperative Group in the GU Committee. He has authored over 160 peer reviewed publications as well as numerous chapters, reviews, and abstracts. He leads a team of over 50 research nurses, coordinators, data managers, regulatory specialists, scientists, and investigators dedicated to discovery science in GU cancers in the laboratory and treatment science in the clinic. As an R01 funded clinical-translational investigator, he has mentored over a dozen medical oncology fellows and junior faculty, and many residents and students both in the clinical, for clinical trials, and for laboratory training.
Sam S. Chang, MD, MBA, Patricia and Rodes Hart Endowed Professor of Urologic Surgery and Oncology at Vanderbilt University Medical Center in Nashville, Tennessee serves as the first Chief Surgical Officer at the Vanderbilt Ingram Cancer Center. Dr. Chang, a graduate of Princeton University and Justin Potter Scholarship Awardee at Vanderbilt Medical School, completed his uro-oncology fellowship as Chief Fellow at Memorial Sloan-Kettering Cancer Center, New York.
Since his return to Nashville, he has focused on urologic oncology and education and has led efforts in integration of evidence-based medicine in clinical pathways, enhanced national guidelines formulation, improved urologic cancer staging, and promoted multi-disciplinary cancer treatment initiatives. He has orchestrated the initiation and expansion of multiple cancer-related treatment protocols at Vanderbilt and elsewhere. Recognized early in his career with a CaPCURE Prostate Cancer Young Investigator award (now Prostate Cancer Foundation Award), Dr. Chang has served as the Chair of the SUO Panel on Hormone Refractory Prostate Cancer, the Chair of the American Joint Committee on Cancer GU Staging Task Force, the Facilitator and Vice-Chair of the Renal Malignancy Follow-Up AUA Guidelines Panel, the Chair of the AUA/ASCO/ASTRO/SUO Guidelines on Non Invasive and Invasive Bladder Cancer, and the Chair of the AUA Prostate Cancer Core Curriculum Committee. He was a former member of the AUA Foundation Prostate Advisory Board and is a current member of the NCCN Bladder Cancer Panel, Chair of the AUA Public Policy Panel, Bladder Cancer Advocacy Network (BCAN)’s Scientific Advisory Board, and the Editor in Chief of the American Board of Urology Examination Committee (2021-2024). He was elected (2018-2022) as Assistant Secretary of the American Urological Association. In 2021, Dr. Chang was also named as a member of the AUA Task Force on Diversity and Inclusion.
While maintaining a busy clinical surgical practice focused on prostate, kidney and bladder cancer, he has recently earned his MBA at Vanderbilt’s Owen School of Business. He completed his term as a nominated Fellow of the Nashville Health Care Council in 2016. Dr. Chang has authored more than 450 original publications and multiple book chapters as well has edited several textbooks. For his academic efforts, he received the SUO’s first-ever Distinguished Service Award and the AUA Gold Cystoscope Award. His mentoring efforts have been recognized with the Society of Women in Urology (SWIU) Christina Manthos Mentoring Award in 2021.
Dr. Yuval Eshdat Ph.D, joined NRS H&W, Israel, at its formation to serve as Chairman of Scientific Advisory and Policy Board. The retired Chief Scientist of the Ministry of Agriculture and Rural Development (2007-12), serves as NRS’s expert in innovative agricultural research & development, biotechnology and bio-economy.
Dr. Eshdat graduated in Chemistry at the Hebrew University in Jerusalem and received its Ph.D. in Biophysics from the Weizmann Institute of Science (1973). He served as research Associate at Yale University Medical School (1974-6) and as Senior Scientist at the Weizmann Institute of Science (1976-1981). At the ARO-Volcani Center (1981-2013) he acted as Principal Scientist (protein chemistry and biotechnology), Head of the Department of Fruit-Tree breeding and Molecular Genetics (1990-1998), and Director of the Institute of Horticulture and Floriculture at the ARO (1998-2002). His scientific work expanded in both fields of agricultural biotechnology and bio-medicine, including international collaboration as senior scientist and visiting professor in several leading research centers.
In 2007, Dr. Eshdat was nominated as Israel’s Chief Scientist of the Ministry of Agriculture and Rural Development, thus directing the public agricultural R&D system in Israel. He was also involved in mediating the worldwide activity of Israel international agricultural research and served in the governing boards of several European Research Area Networks (ERA-Nets), EU Joint program Initiative on agriculture, food security and climate change (FACCE-JPI), the USA-Israel bi-national fund for agricultural research (BARD), and was the national delegate and Member of SCAR (the EU Standing Committee for Agricultural Research) (2007-13).
Currently, Dr. Eshdat acts as consultant to BioHarvest Ltd., Rehovot, Israel and to the Ministry of Agriculture and Rural Development; and Expert, on behalf of Israel Governmental Innovation Authority, to the European Framework Program Committee for Horizon 2020 Societal Challenge 2 Bioeconomy [Food Security, Sustainable Agriculture and Forestry, Marine and Maritime and Inland Water Research and the Bioeconomy, European Commission – DG Research & Innovation]. He also active as Emeritus Principal Scientist (“Research Professor”) at the Institute of Plant Sciences, Agricultural Research Organization, Volcani Center, Israel.
Phillip C. Ginsberg, DO, JD.Dr. Phillip Ginsberg was the Chairman of the Division of Urology at the Albert Einstein Medical Center in Philadelphia for 25 years and is currently Clinical Professor of Urology at the Philadelphia College of Osteopathic Medicine. He was also the Urology Residency Program Director at Einstein, from 1991 to 2019. After graduating from Medical School, he completed a general surgical residency and urological surgical residency at the Albert Einstein Medical Center. He had additional training in urologic oncology at Memorial Sloan-Kettering Cancer Center in New York and in pediatric urology at the Children's' Hospital of Philadelphia.
He has served as the President of the Medical Staff at Einstein, having chaired the institution wide quality performance committee for the five years prior. He is past president of the National Osteopathic Urology Discipline.
As Clinical Professor of Urology, he actively participates in the education of medical students from both PCOM and Jefferson Medical College. He is a member of the American Urological Association, the Mid-Atlantic AUA, the Pennsylvania Urological Association and the Philadelphia Urology Society. In addition, he maintains membership in the American College of Physician Executives, the American College of Legal Medicine and the Philadelphia Medical Society. Dr. Ginsberg has authored several book chapters and multiple scientific articles which have been published in peer reviewed journals. He is in the private practice of Urology, with offices in Northeast Philadelphia, and at the Albert Einstein Medical Center in Philadelphia.
Dr. Ginsberg graduated from the Temple University School of Law in 1995 and is a licensed Pennsylvania attorney, practicing part time in Healthcare Law. He is a member of the American Bar Association and the Healthcare Law section of the ABA and a Fellow in the American College of Legal Medicine.
Dr. Ginsberg enjoys tennis, skiing, sailing and golf, but mostly enjoys the company of his wife, Beth, daughter, Rachel, son, Joshua and two grandchildren, Hudson and London.
Kirsten Greene, MD, MAS, FACS has served as the Paul Mellon Professor and Chair of the UVA Department of Urology since 2019. In this position, she provides urological services to patients in the community and trains the next generation of urologists. She also serves as Associate Chief Medical Officer at UVA Health.
Greene specializes in urologic oncology with a focus on prostate cancer diagnosis and treatment. She is interested in organ preservation and minimally invasive/robotic surgery. Other clinical interests include cancer screening, quality of life assessment and novel imaging technology. Her research efforts focus on surgical device development, robotic surgical techniques and innovations, new forms of imaging for prostate cancer, cancer outcomes research, as well as physician well-being and burnout.
Born in New York and raised in Delaware, Greene completed her undergraduate studies at UVA, where she was an Echols and Jefferson Scholar and received a Bachelor of Arts in interdisciplinary studies in 1995. She then earned her medical degree from the Johns Hopkins University School of Medicine in 2000.
At the University of California, San Francisco (UCSF), Greene was an intern and a resident in the Department of Surgery before completing residency in the Department of Urology. She pursued a Master of Science in Clinical Research with a focus on urologic oncology prior to joining UCSF as a clinical instructor in the Department of Urology, where she was eventually promoted to full professor in 2018. That same year, she also was named to the Frank Hinman Jr., MD Endowed Professorship in Urologic Education.
During her time at UCSF, Greene served as associate chair for education, residency program director, vice chair and chief of the urology service at the San Francisco Veterans Affairs Medical Center (SFVAMC).
In her free time, Greene enjoys spending time with her husband and two Labrador Retrievers and exploring the local vineyards around Charlottesville.
Dr. David Josephson, is attending surgeon and Clinical Division Chief of Urology at Cedars-Sinai Medical Center. Dr. Josephson earned his MD from Albert Einstein College of Medicine and completed a residency in urology at University of Southern California. He subsequently completed a urologic oncology and reconstructive urology fellowship at USC/Norris Comprehensive Cancer Center. He subsequently had fellowship training in advanced laparoscopy and robotic surgery at City of Hope. He is a member of the Society of Urologic Oncology, American Urologic Association, and American College of Surgeons and past president of the Los Angeles Urologic Society.
Dr. Brianne Kent (PhD) is the Canada Research Chair in Translational Neuroscience and Dementia and Assistant Professor at Simon Fraser University. She also holds an appointed position on the Governing Council of the Canadian Institutes of Health Research. Dr. Kent trained as a neuroscientist at Yale University, University of Cambridge, University of British Columbia, and Harvard Medical School. She is an expert in translational methodology, bridging scientific discovery with clinical applications. Her research focuses on early detection and novel therapeutics for Alzheimer’s disease and has been supported by funding agencies in the US, Canada, and UK, including the Gates Cambridge Trust, National Institute of Neurological Disorders and Stroke, and Canada Foundation for Innovation.
Treating people in Georgia for more than three decades, James M. Libby, MD, is now sharing his expertise at Urology of Greater Atlanta. Dr. Libby received his MD degree from Baylor College of Medicine in Houston Texas. He served two years in general surgery at North Shore University Hospital and completed his urology residency and research fellowship in urologic oncology at Baylor College of Medicine.
He is certified by the American Board of Urology and has been in private practice in Atlanta since 1987 as one of the most sought-after urologists in the state of Georgia. He is past president of the Atlanta Urologic Society and Baylor College of Medicine Alumni Association. He is a founding member of Urology of Greater Atlanta, is affiliated with Northside and Piedmont Henry Hospitals. He's been published in numerous medical journals throughout his career and does a lot of professional speaking.
He is married with 4 children, 3 grandchildren and enjoys competitive tennis and spinning.
James McKiernan, MD is the John K. Lattimer Professor and Chairman of the Department of Urology of the College of Physicians and Surgeons and Urologist-in-chief at New York-Presbyterian Hospital/Columbia. The Department of Urology at NYP/Columbia is currently ranked in the top 5 in America in the U.S. News & World Report ranking of America’s best hospitals.
Dr. McKiernan’s clinical practice focuses on urologic oncology, particularly early detection and surgical therapy in high-risk patients. His research focuses on developing novel therapeutics for bladder cancer as well as new platforms for early detection and risk stratification across all urologic cancers.
Dr. McKiernan’s research has been published in Cancer, Cancer Research, the Journal of Clinical Oncology, JAMA Oncology, European Urology, Journal of Urology, Urologic Oncology, and Urology. He has authored and co-authored more than 275 scientific articles and book chapters in the field of urologic oncology.
Angel S. Muntaner Morales, MD is President at Puerto Rico Primary Care MSO Inc. and has been a general healthcare practitioner for more than three decades. As the former President of TCS Inc. Consulting and Chief Medical Officer of the Castellana Health Group. Dr. Morales was an executive leader in business development and healthcare modernization. He is a member of the Board of Directors at E-Health Partner Inc. and Costa Este Medical Group, and received his MD from Universidad Central Del Este School of Medicine.
Dr. Ritch is a fellowship-trained Urologic Oncologist, and currently an Associate Professor of Urology at the University of Miami, Miller School of Medicine. His clinical interests include the treatment of prostate, bladder, kidney and testicular cancer. His research interests are in prostate and bladder cancer. He oversees the institutional non-muscle invasive bladder cancer database at the University of Miami and has conducted a randomized controlled pilot trial investigating the role of nutrition intervention in patients undergoing radical cystectomy. He also has active research studies on prostate cancer in Afro-Caribbean men. He is a member of the AUA Guideline Panel for the Management of Non-muscle Invasive Bladder Cancer and is the Society of Urologic Oncology (SUO) representative to the American College of Surgeons Commission on Cancer (CoC). He did his undergraduate studies at Duke University and then matriculated at the University of Chicago, where he obtained a joint degree in medicine (MD) and business (MBA) from the Pritzker School of Medicine and Booth School of Business. He then completed his residency in Urology at Columbia University Medical Center/NY Presbyterian Hospital followed by a two-year fellowship in Urologic Oncology at Vanderbilt University Medical Center
Dr. Sonn is a urologic oncologist who specializes in prostate and kidney cancer. He has a particular interest in cancer imaging, MRI-Ultrasound fusion targeted prostate biopsy, prostate cancer focal therapy, and robotic surgery for prostate and kidney cancer. His research is focused on developing novel, imaging-based technologies to improve diagnosis and treatment of urologic cancers. He is a member of Stanford Bio-X, the Stanford Cancer Institute, and Associate Member of the Canary Center at Stanford for Cancer Early Detection. He is also a member of the NCCN Prostate Cancer Early Detection panel.
Join a passionate, talented group of scientists, physicians, and business leaders to drive historic change in healthcare
miR Scientific is a majority-owned operating subsidiary of Impact NRS, headquartered in New York with operating subsidiaries in Canada and Israel.
Impact NRS is a leading innovation company developing transformative solutions to address persistent global challenges in human health, sustainable food production and agriculture. Their model incorporates breakthrough advances in science, statistics and computation to develop products and services for early and scalable adoption. Impact NRS collaborates with stakeholders worldwide to enable rapid commercialization of their ESG socially responsible initiatives.